Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 1/20 | 0.59 |
| ▸ | LMNA | P02545 | 2/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | USP2 | O75604 | 1/20 | 0.45 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.34 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3067831 | 1.00 | PDE4A (0.59) | PDE4ALMNATDP1L3MBTL1USP2 | |
| SCHEMBL19952978 | 1.00 | PDE4A (0.59) | PDE4ALMNATDP1L3MBTL1USP2 | |
| SCHEMBL19952979 | 1.00 | PDE4A (0.59) | PDE4ALMNATDP1L3MBTL1USP2 | |
| SCHEMBL288150 | 1.00 | PDE4A (0.59) | PDE4ALMNATDP1L3MBTL1USP2 | |
| SCHEMBL29563836 | 1.00 | PDE4A (0.59) | PDE4ALMNATDP1L3MBTL1USP2 | |
| SCHEMBL2135451 | 0.92 | PDE4A (0.55) | PDE4ALMNATDP1L3MBTL1USP2 | |
| SCHEMBL887710 | 0.92 | PDE4A (0.55) | PDE4ALMNATDP1L3MBTL1USP2 | |
| SCHEMBL3764484 | 0.82 | PDE4A (0.44) | PDE4ALMNATDP1L3MBTL1USP2 | |
| SCHEMBL14940504 | 0.82 | PDE4A (0.44) | PDE4ALMNATDP1L3MBTL1USP2 | |
| SCHEMBL677609 | 0.82 | PDE4A (0.44) | PDE4ALMNATDP1L3MBTL1USP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8063107-B2 | Use of trans-pellitorin as flavor substance | SYMRISE AG (DE) | 2011-11-22 | — | — | US | disclosed |
| US-20100291005-A1 | USE OF TRANS-PELLITORIN AS FLAVOR SUBSTANCE | SYMRISE GMBH & CO. KG (DE) | 2010-11-18 | — | — | US | disclosed |
| US-7776923-B2 | Use of trans-pellitorin as flavor substance | SYMRISE GMBH & CO. KG (DE) | 2010-08-17 | — | — | US | disclosed |
| US-20040241312-A1 | Use of 2E,4E-decadienoic acid isobutylamide for imparting a salivation inducing effect to a foodstuff, an oral hygiene preparation or a gourmet or snack preparation; preparation by amidating a dodecadienoate with isobutylamine | SYMRISE AG (DE) | 2004-12-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100291005-A1 | USE OF TRANS-PELLITORIN AS FLAVOR SUBSTANCE | PTMA, TAS2R14, TAS2R16 | PDE4A 764/4885LMNA 3818/4885TDP1 2780/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.